Total Teams – Page 2 – Dracen Pharmaceutical

Margaret Dugan, M.D.

Dr. Dugan joined Dracen Pharmaceuticals in 2018 with 20 + years of experience as a senior leader, more recently as Senior Vice-President, in Novartis oncology global strategic drug development and portfolio management, including translational science, early and late clinical development, Continue reading →

Mohamed Ragab, M.D.

A founding executive of Dracen, Dr. Ragab was most recently the Vice President, Search and Evaluation, Oncology at Bristol-Myers Squibb where he was involved in many major immuno-oncology deals. Prior to that, he was Global Partnering Head, Oncology at Hoffman-La Continue reading →

Dennis Bilski

Mr. Bilski has more than 20 years of experience in accounting, finance, strategic planning, and executive management for public and private companies. Mr. Bilski was the Chief Financial Officer of Tragara Pharmaceuticals, Inc. from 2007-2018. Prior to Tragara, Mr. Bilski Continue reading →

Robert Wild, Ph.D.

Dr. Wild joined Dracen Pharmaceuticals in 2017 as one of the founding executives and Chief Scientific Officer (CSO). He is responsible for all discovery, preclinical development and translational research efforts of Dracen’s therapeutic pipeline and leads scientific strategy. Dr. Wild Continue reading →

Thomas Estok

Mr. Estok brings 30+ years of experience in development and commercialization of pharmaceuticals to Dracen. Previously, he was the founding President/CEO of Tragara Pharmaceuticals, founding President/CEO of Cabrellis Pharmaceuticals where he led the organization’s development of amrubicin prior to Continue reading →